within Pharmacolibrary.Drugs.ATC.L;

model L01EJ03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 19.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.267,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013166666666666667,
    Tlag           = 18.6
  );

  annotation(Documentation(
    info ="<html><body><p>Pacritinib is an oral, selective inhibitor of Janus-associated kinases JAK2 and FLT3 used for the treatment of myelofibrosis, particularly in patients with thrombocytopenia. It is approved for use in several countries for adults with intermediate- or high-risk primary or secondary myelofibrosis.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported in adult patients with myelofibrosis, following oral administration as part of clinical development.</p><h4>References</h4><ol><li><p>Jeon, JY, et al., &amp; Bhatnagar, B (2020). Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. <i>Investigational new drugs</i> 38(2) 340–349. DOI:<a href=&quot;https://doi.org/10.1007/s10637-019-00786-4&quot;>10.1007/s10637-019-00786-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31102119/&quot;>https://pubmed.ncbi.nlm.nih.gov/31102119</a></p></li><li><p>Nunez, M, et al., &amp; Ondieki, D (2024). Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(11-12) 1023–1036. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2401603&quot;>10.1080/17425255.2024.2401603</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39252171/&quot;>https://pubmed.ncbi.nlm.nih.gov/39252171</a></p></li><li><p>Sunkara, PK, et al., &amp; Ramakrishna, K (2024). Development and validation of an LC-MSMS method for the quantitation of pacritinib; application of kinetics in rabbits. <i>Journal of pharmacological and toxicological methods</i> 129 107547–None. DOI:<a href=&quot;https://doi.org/10.1016/j.vascn.2024.107547&quot;>10.1016/j.vascn.2024.107547</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39069107/&quot;>https://pubmed.ncbi.nlm.nih.gov/39069107</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EJ03;
